Tuesday, 15 Oct 2019

You are here

Uncertain Long Term Efficacy in Trials of Knee Osteoarthritis

A systematic review and network meta-analysis of 47 randomized clinical trials in knee osteoarthritis finds uncertainty around estimates of effect size for pain scores thereby casting uncertainty over the long-term efficacy of medications for knee osteoarthritis.

JAMA reports a network meta-analysis of 47 RCTs (lasting from 1-4 years), involving 22 037 patients; mostly 55-70 years, with knee osteoarthritis who are randomized to receive analgesics; antioxidants; bone-acting agents (e.g., bisphosphonates) nonsteroidal anti-inflammatory drugs (NSAIDS); intra-articular injections (hyaluronic acid or corticosteroids), glucosamine and chondroitin sulfate; and newer agents such as cindunistat and sprifermin.

Decreases in pain were only evident with celecoxib (standardized mean difference [SMD], −0.18) and glucosamine sulfate (SMD, −0.29). For all other estimates, there was large uncertainty compared to placebo.

Associations with improvement in joint space narrowing were found for glucosamine sulfate (SMD, −0.42 [95% CrI, −0.65 to −0.19]), chondroitin sulfate (SMD, −0.20 [95% CrI, −0.31 to −0.07]), and strontium ranelate (SMD, −0.20 [95% CrI, −0.36 to −0.05]).

These analyses again underscore the lack of good clinical trial designs, outcome measures and outcomes for the most prevalent form of arthritis - osteoarthritis of the knee. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Sprifermin Benefits Cartilage Loss but not Symptoms in Knee Osteoarthritis

Intra-articular sprifermin given to patients with symptomatic and radiographic knee osteoarthritis has been shown to significantly improve total femorotibial joint cartilage thickness after 2 years, but without significant clinical benefits. Which begs the question, why is there a disconnect between radiographic disease modification (cartilage thickness) and symptomatic improvement?

Bisphosphonates and the Risk of Osteonecrosis of the Jaw

Even though oral bisphosphonates are widely used, there is an inordinate concern over the risk of osteonecrosis of the jaw (ONJ). A new UK study suggests that the risk of ONJ is elevated six fold by the use of biphosphonates.

ASBMR Recommendations on Secondary Fracture Prevention

The American Society for Bone and Mineral Research has developed multistakeholder consensus clinical recommendations for the prevention of secondary fractures for those aged 65 years and older after an initial hip or vertebral fracture.

Overall they have promoted 13 recommendations (7 primary and 6 secondary) strongly supported medical evidence.

Highlights include recommendations for:

Similar Outcomes for Hip Arthroplasty or Hemiarthroplasty in Hip Fracture

The NEJM reports on a randomized comparison of hemiarthroplasty and total hip arthroplasty in displaced femoral neck fractures and shows no difference in function and quality of life over 24 months.

Need for Pre-operative Hyperglycemia Testing Prior to Total Joint Replacement

JAMA reports on a large Medicare cohort study showing that amongst patients undergoing total joint replacement (TJR), preoperative HbA1c testing was performed in 26% to 43% of patients with diabetes and in only 5% of those without diabetes. Importantly research has shown that an elevated HbA1c level is associated with postoperative complications.